Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06182969 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 16, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Site contact updatedv5
  2. Site contact updated Eligibility criteria expanded, about 2 wordsv4 Show 1 more changeShow less
    • Eligibility criteria expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Oct 2024 to Aug 9, 2024 · Site details revisedv3 Show 2 more changesShow less
    • Start date changed from estimate of Oct 2024 to Aug 9, 2024
    • Site details revised
  4. Start date: Dec 2023 to Oct 2024v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the safety, tolerability, pharmacokinetics and pharmacokinetics of multi-dose APG-2575 in mild-to-moderate systemic lupus erythematosus (SLE).
Trial Details
NCT Number NCT06182969
Lead Sponsor Ascentage Pharma Group Inc.
Collaborators: Suzhou Yasheng Pharmaceutical Co., Ltd.
Conditions SLE
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov